EMA takes positive stance on Moderna COVID-19 vaccine for adolescents

By The Science Advisory Board staff writers

July 26, 2021 -- The European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has taken a positive position on marketing authorization for Moderna's COVID-19 vaccine for use in adolescents 12 years of age and older.

Following the EMA's nod, the European Commission will now consider authorizing the use of Moderna's vaccine in this population, Moderna said.

The company is now conducting a clinical study regarding use of its vaccine in children ages 6 months to less than 12 years, according to the firm.

Moderna files U.S. EUA for COVID-19 vaccine in adolescents
Moderna announced it has requested an emergency use authorization (EUA) from the U.S. Food and Drug Administration for its COVID-19 vaccine in adolescents.
Moderna, Medison partner on Moderna's COVID-19 vaccine
Moderna and Medison Pharma announced that they are entering into a marketing agreement for Moderna's COVID-19 vaccine across central Europe and Israel.
Moderna initiates rolling BLA for COVID-19 vaccine
Moderna has started the rolling submission process with the U.S. Food and Drug Administration for a biologics license application (BLA) for the use of...
Thermo, Moderna ink COVID-19 vaccine manufacturing deal
Moderna has signed a deal with Thermo Fisher Scientific to provide manufacturing services and supply packaging for its COVID-19 vaccine.
Moderna vaccine 100% effective for teens
Moderna announced its phase II/III study of its COVID-19 vaccine in adolescents has met its primary immunogenicity endpoint with no cases of COVID-19...

Copyright © 2021 scienceboard.net


Conferences
Connect
Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter